4.4 Article

Dynamic Imaging of Cell-Free and Cell-Associated Viral Capture in Mature Dendritic Cells

Journal

TRAFFIC
Volume 12, Issue 12, Pages 1702-1713

Publisher

WILEY-BLACKWELL
DOI: 10.1111/j.1600-0854.2011.01281.x

Keywords

dendritic cells; HIV-1; live cell imaging; trans-infection

Categories

Funding

  1. Spanish Ministry of Education and Science [SAF2007-64696, SAF2010-21224, MAT2007-66629-C02-01]
  2. Spanish AIDS network 'Red Tematica Cooperativa de Investigacion en SIDA' [RD06/0006]
  3. Catalan HIV Vaccine Development Program (HIVACAT)
  4. Generalitat de Catalunya [2009 SRG 597]
  5. [BES-2008-002609]
  6. ICREA Funding Source: Custom

Ask authors/readers for more resources

Dendritic cells (DCs) capture human immunodeficiency virus (HIV) through a non-fusogenic mechanism that enables viral transmission to CD4(+) T cells, contributing to in vivo viral dissemination. Although previous studies have provided important clues to cell-free viral capture by mature DCs (mDCs), dynamic and kinetic insight on this process is still missing. Here, we used three-dimensional videomicroscopy and single-particle tracking approaches to dynamically dissect both cell-free and cell-associated viral capture by living mDCs. We show that cell-free virus capture by mDCs operates through three sequential phases: virus binding through specific determinants expressed in the viral particle, polarized or directional movements toward concrete regions of the cell membrane and virus accumulation in a sac-like structure where trapped viral particles display a hindered diffusive behavior. Moreover, real-time imaging of cell-associated viral transfer to mDCs showed a similar dynamics to that exhibited by cell-free virus endocytosis leading to viral accumulation in compartments. However, cell-associated HIV type 1 transfer to mDCs was the most effective pathway, boosted throughout enhanced cellular contacts with infected CD4(+) T cells. Our results suggest that in lymphoid tissues, mDC viral uptake could occur either by encountering cell-free or cell-associated virus produced by infected cells generating the perfect scenario to promote HIV pathogenesis and impact disease progression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Microbiology

Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells

Judith Grau-Exposito, David Perea, Marina Suppi, Nuria Massana, Ander Vergara, Maria Jose Soler, Benjamin Trinite, Julia Blanco, Javier Garcia-Perez, Jose Alcami, Anna Serrano-Mollar, Joel Rosado, Vicenc Falco, Meritxell Genesca, Maria J. Buzon

Summary: We developed a rapid platform for studying SARS-CoV-2 by using primary human lung tissue cells directly, which can identify viral targets, express viral entry factors, and screen viral entry inhibitors and anti-inflammatory compounds. The method preserves main immune and structural cell populations, including the most susceptible cell targets for SARS-CoV-2, and maintains the expression of proteins involved in viral infection. Additionally, the method allows for highly reproducible antiviral testing and provides the identification of new compounds missed by conventional systems like VeroE6.

PLOS PATHOGENS (2023)

Article Virology

Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction

Clara Duran-Castells, Anuska Llano, Ai Kawana-Tachikawa, Anna Prats, Ignacio Martinez-Zalacain, Mie Kobayashi-Ishihara, Bruna Oriol-Tordera, Ruth Pena, Cristina Galvez, Sandra Silva-Arrieta, Bonaventura Clotet, Eva Riveira-Munoz, Esther Ballana, Julia. G. Prado, Javier Martinez-Picado, Jorge Sanchez, Beatriz Mothe, Dennis Hartigan-O'Connor, Tony Wyss-Coray, Andreas Meyerhans, Magnus Gisslen, Richard. W. Price, Carles Soriano-Mas, Jose Antonio Munoz-Moreno, Christian Brander, Marta Ruiz-Riol

Summary: High levels of SIRT2 are associated with uncontrolled HIV infection, plasma viral load, and proviral levels. SIRT2 levels are also linked to markers of neurological damage and brain involution, especially in individuals who initiate cART later. Inhibition of SIRT2 could potentially be a therapeutic target for HIV infections and their associated neurological dysfunction.

JOURNAL OF VIROLOGY (2023)

Article Oncology

Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS-CoV-2 mRNA-1237 vaccine in patients with solid tumors

Eudald Felip, Edwards Pradenas, Margarita Romeo, Silvia Marfil, Benjamin Trinite, Victor Urrea, Ainhoa Hernandez, Ester Ballana, Marc Cucurull, Lourdes Mateu, Marta Massanella, Bonaventura Clotet, Teresa Moran, Julia Blanco

Summary: Patients with solid tumors have a higher risk of complications, hospitalizations, or death during the SARS-CoV-2 pandemic. The immunosuppressive state of cancer treatments or the tumor itself may affect the development of vaccination antibodies. This study emphasizes the importance of prioritizing cancer patients receiving anticancer treatment in SARS-CoV-2 vaccination programs.

MOLECULAR ONCOLOGY (2023)

Article Multidisciplinary Sciences

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

Antonio Barreiro, Antoni Prenafeta, Gregori Bech-Sabat, Merce Roca, Eva Perozo Mur, Ricard March, Luis Gonzalez-Gonzalez, Laia Madrenas, Julia Corominas, Alex Fernandez, Alexandra Moros, Manuel Canete, Merce Molas, Thais Pentinat-Pelegrin, Clara Panosa, Alberto Moreno, Ester Puigvert Molas, Eva Pol Vilarrassa, Jordi Palmada, Carme Garriga, Teresa Prat Cabanas, Javier Iglesias-Fernandez, Julia Vergara-Alert, Cristina Lorca-Oro, Nuria Roca, Leira Fernandez-Bastit, Jordi Rodon, Monica Perez, Joaquim Segales, Edwards Pradenas, Silvia Marfil, Benjamin Trinite, Raquel Ortiz, Bonaventura Clotet, Julia Blanco, Jorge Diaz Pedroza, Rosa Ampudia Carrasco, Yaiza Rosales Salgado, Jordina Loubat-Casanovas, Sara Capdevila Larripa, Julia Garcia Prado, Jordi Barretina, Marta Sistere-Oro, Paula Cebollada Rica, Andreas Meyerhans, Laura Ferrer

Summary: Current COVID-19 vaccines have shown effectiveness in reducing infection rates, severe disease, and mortality. However, due to the continuous evolution of SARS-CoV-2 variants, the development of new accessible vaccines is necessary. This study presents preclinical data on a recombinant protein vaccine, PHH-1V, which was effective in inducing immune responses and preventing mortality in mice infected with SARS-CoV-2 variants.

ISCIENCE (2023)

Article Chemistry, Multidisciplinary

Hybrid Plasmonic Nanostructures for Enhanced Single-Molecule Detection Sensitivity

Ediz Kaan Herkert, Domenica Romina Bermeo Alvaro, Martina Recchia, Wolfgang Langbein, Paola Borri, Maria F. Garcia-Parajo

Summary: Biosensing applications often require single-molecule sensitivity in the presence of strong background signals. Plasmonic nanoantennas can confine and enhance light in volumes far below the diffraction limit, making them suitable for these tasks. Hybrid AiB platforms made of both gold and aluminum promise superior performance by providing better background screening and additional enhancements.

ACS NANO (2023)

Article Oncology

Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines

Carmen Aguilar-Gurrieri, Ana Barajas, Carla Rovirosa, Raquel Ortiz, Victor Urrea, Nuria de la Iglesia, Bonaventura Clotet, Julia Blanco, Jorge Carrillo

Summary: Neoantigens are tumor-specific antigens that can elicit a specific immune response. They have potential for the development of personalized cancer vaccines. The presentation of neoantigens to T cells is influenced by vaccine delivery strategies, including the use of specific linkers. The efficiency of neoantigen processing and presentation by MHC-I molecules can be improved with alanine-based linkers.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)

Article Biochemistry & Molecular Biology

Exploring FeLV-Gag-Based VLPs as a New Vaccine Platform-Analysis of Production and Immunogenicity

Raquel Ortiz, Ana Barajas, Anna Pons-Grifols, Benjamin Trinite, Ferran Tarres-Freixas, Carla Rovirosa, Victor Urrea, Antonio Barreiro, Anna Gonzalez-Tendero, Maria Cardona, Laura Ferrer, Bonaventura Clotet, Jorge Carrillo, Carmen Aguilar-Gurrieri, Julia Blanco

Summary: Feline leukemia virus (FeLV) is a common infectious disease in domestic cats, and current vaccines do not provide full protection. This study proposes using HIV-1 Gag-based VLPs as a novel vaccine strategy against FeLV. The immunogenicity of selected candidates was evaluated in mice, showing strong immune responses to Gag but failing to generate antibodies against p15E.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Multidisciplinary Sciences

Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2

Jordana Munoz-Basagoiti, Fabio Luis Lima Monteiro, Lauren R. H. Krumpe, Victoria Armario-Najera, Shilpa R. Shenoy, Daniel Perez-Zsolt, Harrison James Westgarth, Gemma Villorbina, Larissa Maciel Bomfim, Dalia Raich-Regue, Lara Nogueras, Curtis J. Henrich, Marcal Gallemi, Filipe Romero Rebello Moreira, Pascual Torres, Jennifer Wilson, Mirela D'arc, Silvia Marfil, Alice Laschuk Herlinger, Edwards Pradenas, Luiza Mendonca Higa, Manuel Portero-Otin, Benjamin Trinite, Richard M. Twyman, Teresa Capell, Amilcar Tanuri, Julia Blanco, Nuria Izquierdo-Useros, Elibio L. Rech, Paul Christou, Barry R. O'Keefe

Summary: SARS-CoV-2 is a coronavirus responsible for the COVID-19 pandemic. Targeting the glycosylated Spike protein on the virus surface can prevent infections. Cyanovirin-N (CV-N), a lectin from cyanobacteria, can selectively target SARS-CoV-2 Spike glycans and inhibit viral infection in vitro and in vivo, showing potential as a broad-spectrum antiviral agent.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Review Virology

Opportunities for CAR-T Cell Immunotherapy in HIV Cure

Gerard Campos-Gonzalez, Javier Martinez-Picado, Talia Velasco-Hernandez, Maria Salgado

Summary: Chimeric antigen receptor (CAR) technology has had a significant impact on the treatment of blood malignancies, particularly various types of leukemia. However, applying this technology to HIV treatment presents numerous challenges that hinder its widespread adoption.

VIRUSES-BASEL (2023)

Article Multidisciplinary Sciences

Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization

Edwards Pradenas, Silvia Marfil, Victor Urrea, Macedonia Trigueros, Tetyana Pidkova, Anna Pons-Grifols, Raquel Ortiz, Carla Rovirosa, Ferran Tarres-Freixas, Carmen Aguilar-Gurrieri, Ruth Toledo, Anna Chamorro, Marc Noguera-Julian, Lourdes Mateu, Ignacio Blanco, Eulalia Grau, Marta Massanella, Jorge Carrillo, Bonaventura Clote, Benjamin Trinite, Julia Blanco

Summary: The development of cross-variant neutralizing antibodies against SARS-CoV-2 is an important goal for COVID-19 vaccine strategies. This study analyzed the neutralization titers of plasma from different groups based on vaccine doses and infection history. Two doses of vaccine had limited efficacy in generating cross-neutralizing antibodies against Omicron variants in uninfected individuals, but showed synergy with natural immunization in convalescent individuals. Booster doses significantly broadened the cross-neutralizing response in uninfected individuals and improved responses in convalescent individuals. Omicron breakthrough infections also improved cross-neutralization in vaccinated individuals. Overall, ancestral Spike-based immunization, through infection or vaccination, helps broaden SARS-CoV-2 humoral immunity.

ISCIENCE (2023)

Article Health Care Sciences & Services

Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial

Julia Corominas, Carme Garriga, Antoni Prenafeta, Alexandra Moros, Manuel Canete, Antonio Barreiro, Luis Gonzalez-Gonzalez, Laia Madrenas, Irina Guell, Bonaventura Clotet, Nuria Izquierdo-Useros, Dalia Raich-Regue, Marcal Gallemi, Julia Blanco, Edwards Pradenas, Benjamin Trinite, Julia G. Prado, Oscar Blanch-Lombarte, Raul Perez-Caballero, Montserrat Plana, Ignasi Esteban, Carmen Pastor-Quinones, Xavier Nunez-Costa, Rachel Abu Taleb, Paula McSkimming, Alex Soriano, Jocelyn Nava, Jesse Omar Anagua, Rafel Ramos, Ruth Marti Lluch, Aida Corpes Comes, Susana Otero Romero, Xavier Martinez Gomez, Carla Sans-Pola, Jose Molto, Susana Benet, Lucia Bailon, Jose R. Arribas, Alberto M. Borobia, Javier Queiruga Parada, Jorge Navarro-Perez, Maria Jose Forner Giner, Rafael Orti Lucas, Maria del Mar Vazquez Jimenez, Salvador Ona Compan, Melchor Alvarez-Mon, Daniel Troncoso, Eunate Arana-Arri, Susana Meijide, Natale Imaz-Ayo, Patricia Munoz Garcia, Sofia de la Villa Martinez, Sara Rodriguez Fernandez, Teresa Prat, Elia Torroella, Laura Ferrer

Summary: In the interim results of the Phase IIb HH-2 trial, the SARS-CoV-2 protein-based heterodimer vaccine PHH-1V is shown to have a stronger immunogenicity and higher safety compared to the homologous booster BNT162b2. The PHH-1V booster induces a superior neutralizing antibody response against various SARS-CoV-2 variants and also elicits a strong T-cell response.

LANCET REGIONAL HEALTH-EUROPE (2023)

Article Biochemistry & Molecular Biology

Exploring the HIV-1 Rev Recognition Element (RRE)-Rev Inhibitory Capacity and Antiretroviral Action of Benfluron Analogs

Sergi Chumillas, Saurabh Loharch, Manuela Beltran, Mateusz P. Szewczyk, Silvia Bernal, Maria C. Puertas, Javier Martinez-Picado, Jose Alcami, Luis M. Bedoya, Vicente Marchan, Jose Gallego

Summary: This study explored the optimization of the antiretroviral properties of benfluron and found that both the benzo[c] and cyclopentanone components are essential for its activity. The results provide insights for the design of new anti-HIV agents targeting the inhibition of Rev function.

MOLECULES (2023)

Article Immunology

Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate

Alexandra Moros, Antoni Prenafeta, Antonio Barreiro, Eva Perozo, Alex Fernandez, Manuel Canete, Luis Gonzalez, Carme Garriga, Edwards Pradenas, Silvia Marfil, Julia Blanco, Paula Cebollada Rica, Marta Sistere-Oro, Andreas Meyerhans, Teresa Prat Cabanas, Ricard March, Laura Ferrer

Summary: The development of a new generation of efficacious vaccines is crucial due to the high global incidence of COVID-19 and low vaccination rates. Researchers have developed an adjuvanted vaccine candidate, PHH-1V, based on a protein fusion of the receptor binding domain (RBD) from the Beta variant of SARS-CoV-2 and the equivalent domain from the Alpha variant. In pig models, PHH-1V has demonstrated excellent safety and has induced a robust immune response to SARS-CoV-2, including neutralising antibodies to multiple variants.

VACCINE (2023)

Article Multidisciplinary Sciences

Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates

Antoni Prenafeta, Gregori Bech-Sabat, Alexandra Moros, Antonio Barreiro, Alex Fernandez, Manuel Canete, Merce Roca, Luis Gonzalez-Gonzalez, Carme Garriga, Joachim Confais, Marion Toussenot, Hugues Contamin, Andres Pizzorno, Manuel Rosa-Calatrava, Edwards Pradenas, Silvia Marfil, Julia Blanco, Paula Cebollada Rica, Marta Sistere-Oro, Andreas Meyerhans, Cristina Lorca, Joaquim Segales, Teresa Prat, Ricard March, Laura Ferrer

Summary: SARS-CoV-2 emerged in December 2019 and continues to spread, necessitating the development of accessible second-generation vaccines. The PHH-1V vaccine candidate, previously developed, shows efficacy in cynomolgus macaques by inducing high levels of antibodies and cellular immune response. Vaccination with PHH-1V prevents viral replication and reduces viral load in respiratory tracts after experimental infection, suggesting its potential use in humans.

ISCIENCE (2023)

Article Hematology

Demonstration of Antibodies Against SARS-CoV-2, Neutralizing or Binding, in Seroconversion Panels After mRNA-1273, BNT-162b2, and Ad26.COV2.S Vaccine Administration

Francisco Belda, Oscar Mora, Monica Lopez-Martinez, Nerea Torres, Ana Vivanco, Silvia Marfil, Edwards Pradenas, Marta Massanella, Julia Blanco, Rebecca Christie, Michael Crowley

Summary: This observational study characterizes the generation of antibodies against SARS-CoV-2 spike protein after vaccination with different COVID-19 vaccines and their neutralizing activity. Age and prior SARS-CoV-2 infection affect the vaccine response. The findings are important for understanding vaccine efficacy and developing antibody assays.

PLASMATOLOGY (2023)

No Data Available